Page last updated: 2024-12-10

mr 2266

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

MR 2266: RN refers to (2R-(2 alpha,6 alpha,11R*))-isomer; structure kappa opioid receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3034816
SCHEMBL ID4404993
MeSH IDM0088736

Synonyms (16)

Synonym
mr 2266
(+/-)-2-(3-furylmethyl)-2'-hydroxy-5,9alpha-diethyl-6,7-benzomorphan hydrochloride
2,6-methano-3-benzazocin-8-ol, 6,11-diethyl-3-(3-furanylmethyl)-1,2,3,4,5,6-hexahydro-, (2r,6r,11r)-
mrz 2266 bs
(-)-mr 2266
(-)-2-(3-furylmethyl)-5,9-diethyl-2'-hydroxy-6,7-benzomorphan
2,6-methano-3-benzazocin-8-ol, 6,11-diethyl-3-(3-furanylmethyl)-1,2,3,4,5,6-hexahydro-, (2r-(2alpha,6alpha,11r*))-
mr-2266-bs
mr-2266
56649-76-4
cas_56649-76-4
bdbm82508
mr2266
SCHEMBL4404993
DTXSID80972094
6,11-diethyl-3-[(furan-3-yl)methyl]-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol

Research Excerpts

Treatment

ExcerptReferenceRelevance
"treatment with MR 2266 (0.3 mg/kg) but was unaffected by naloxone (0.3 mg/kg)."( Peripheral antagonistic action of trimebutine and kappa opioid substances on acoustic stress-induced gastric motor inhibition in dogs.
Buéno, L; Gué, M; Hondé, C; Junien, JL; Pascaud, X, 1988
)
0.61

Dosage Studied

ExcerptRelevanceReference
" A dose-response study demonstrated that the maximum growth hormone release was obtained with 10 micrograms/kg while higher doses were less or not effective."( The growth hormone secretory response to fentanyl in rat: an involvement of mu type receptors.
Buydens, P; Finné, E; Govaerts, J; Matton, A; Vanhaelst, L, 1990
)
0.28
" In order to investigate the possible actions of peripheral, endogenous kappa agonists, a dose-response curve was generated in the place conditioning paradigm from separate groups of naive rats injected with various intraperitoneal doses of the specific kappa antagonist Mr2266 (0."( Kappa receptors mediate the peripheral aversive effects of opiates.
Bechara, A; van der Kooy, D, 1987
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (166)

TimeframeStudies, This Drug (%)All Drugs %
pre-199095 (57.23)18.7374
1990's65 (39.16)18.2507
2000's6 (3.61)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.90 (24.57)
Research Supply Index5.18 (2.92)
Research Growth Index4.08 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (1.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other173 (98.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]